We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+104.41%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$326M
Cap. Flow
-$171M
Cap. Flow %
-10.24%
Top 10 Hldgs %
58.94%
Holding
43
New
12
Increased
5
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$80.5M
2
MGNX icon
MacroGenics
MGNX
+$70.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$70M
4
CGEN icon
Compugen
CGEN
+$55M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$52.9M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$128M
2
QURE icon
uniQure
QURE
+$58M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$54.1M
4
EPZM
Epizyme, Inc
EPZM
+$51.3M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$41M

Sector Composition

Rank Sector Weight
1 Healthcare 85.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
26
DELISTED
Aravive, Inc. Common Stock
ARAV
$11.2M 0.67%
+964,456
New +$11.4M
SIOX
27
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$10.3M 0.62%
3,653,303
– –
ADMA icon
28
ADMA Biologics
ADMA
$2.33B
$7.79M 0.47%
2,658,290
-725,000
-21% -$2.08M
SLNO
29
DELISTED
Soleno Therapeutics
SLNO
$6.75M 0.4%
+202,667
New +$8.78M
QURE icon
30
uniQure
QURE
$3.15B
$2.25M 0.14%
50,000
-982,636
-95% -$58M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$327K 0.02%
10,000
– –
SILK
32
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$209K 0.01%
+5,000
New +$192K
AXGN icon
33
Axogen
AXGN
$2.38B
– –
-3,566,054
Closed -$37.1M
CHRS icon
34
Coherus Oncology
CHRS
$194M
– –
-2,020,002
Closed -$32.8M
KRYS icon
35
Krystal Biotech
KRYS
$9.55B
– –
-654,586
Closed -$28.3M
TVTX icon
36
Travere Therapeutics
TVTX
$5.89B
– –
-2,314,421
Closed -$33.8M
UTHR icon
37
United Therapeutics
UTHR
$22.6B
– –
-1,350,360
Closed -$128M
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.24B
– –
-1,979,669
Closed -$22.4M
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-1,654,600
Closed -$25.4M
EPZM
40
DELISTED
Epizyme, Inc
EPZM
– –
-3,304,918
Closed -$51.3M
OXFD
41
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-1,244,460
Closed -$11.5M
PRNB
42
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-689,718
Closed -$41M
BEAT
43
DELISTED
BioTelemetry, Inc.
BEAT
– –
-49,219
Closed -$1.9M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Consonance Capital Management held 43 positions worth $1.67B, up 24% from $1.34B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Consonance Capital Management withdrew a net $171M in Q2 2020, closing 11 positions and reducing 11 holdings. Its most notable exit was United Therapeutics, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Mersana Therapeutics worth $138M.

  • Consonance Capital Management's largest Q2 2020 buy was Mersana Therapeutics: 235,853 shares worth $138M.
  • Consonance Capital Management added most to Kiniksa Pharmaceuticals in Q2 2020, an estimated $12.6M increase.
  • Consonance Capital Management's biggest Q2 2020 reduction was uniQure, cutting an estimated $58M.
  • Consonance Capital Management fully exited United Therapeutics in Q2 2020, selling an estimated $128M.
  • Consonance Capital Management's ten largest holdings make up 59% of its $1.67B portfolio in Q2 2020.
  • Consonance Capital Management opened 12 new positions and closed 11 in Q2 2020.
  • Consonance Capital Management's portfolio value rose 24% quarter-over-quarter to $1.67B.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.